Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tysabri Production Continues Ahead Of Possible Reintroduction

This article was originally published in The Pink Sheet Daily

Executive Summary

Biogen Idec is manufacturing Tysabri at a slower rate since marketing of the MS therapy was suspended in late February, CEO Mullen says. Continued manufacturing is "prudent at this point," the firm says. Production pause provides an opportunity to enhance manufacturing facilities and processes.

You may also be interested in...



FDA Repeats Birth-Defect Risk With Roche, Novartis Transplant Drugs

PML could be a hazard, too, agency says.

FDA Repeats Birth-Defect Risk With Roche, Novartis Transplant Drugs

PML could be a hazard, too, agency says.

Biogen Idec Adds Liver Warning To Multiple Sclerosis Therapy Avonex

Interferon beta product joins Serono/Pfizer's Rebif with warning reflecting postmarketing experiences. Berlex' Betaseron does not have a warning but recommends testing. Coming on the heels of the Tysabri withdrawal, the labeling change is the second recent setback for Biogen Idec's multiple sclerosis franchise.

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel